Oligonucleotide-cyclopropapyrroloindole conjugates as sequence specific hybridization and crosslinking agents for nucleic acids

Claim 2

A covalently linked oligonucleotide and crosslinking agent conjugate wherein the sequence of the oligonucleotide is complementary or substantially complementary to a target sequence in nucleic acid, the conjugate having the formula R-LINKER-[X--(P═O)(Y)].sub.q --ODN where q is an integer selected from 0 or 1; the X--(P═O)(Y)-- group is at the 3' or 5' end or at both ends of the ODN; X is O or S; Y is O - , S - or CH 3 ; ODN is an oligonucleotide of approximately 3 to 500 nucleotide units, wherein the sugar moiety attached to the heterocyclic bases of the nucleotides is independently selected from β 2-deoxyribofuranose, and β-2-OR'-ribofuranose where R' is C 1-5 -alkyl or C 2-5 -alkenyl, the internudeotide linkages may optionally and independently include phosphorothioate and methylphosphonate linkages, and the ODN may optionally include an intercalator group, reporter group, lipophilic group or a minor groove binder covalently attached to the ODN; the LINKER is a divalent moiety forming a covalent linkage between the ODN and (X--(P═O)(Y)) q groups, of approximately 2 to 30 atoms length, and R is a group selected from the formulas (i) and (ii) ##STR8## where R 1 and R 2 independently are H, alkyl of 1 to 6 carbons, alkoxy of 1 to 6 carbons, phenyl, (C 1-6 alkyl)phenyl, heterocyclic consisting of a 5 to 7 membered ring and including 1 to 3 heteroatoms independently selected from the group consisting of O, N and S, (C 1-6 alkyl)heterocyclic, or the R 1 and R 2 groups jointly form a carbocyclic ring of 5 to 7 atoms or a (C 1-6 alkyl)carbocyclic ring of 5 to 7 atoms, a heterocyclic or a (C 1-6 alkyl)heterocyclic ring where heterocyclic is defined as above, with the proviso that R 1 and R 2 are not both selected from the group consisting of phenyl, (C 1-6 alkyl)phenyl, heterocyclic and (C 1-6 alkyl)heterocyclic; R 3 is H or a group cleavable under physiological conditions; R 4 is a leaving group, with the further proviso that when q is 0 then the LINKER group is attached to the 5 position of a uracil or to the 8 position of a purine base of a 5' or 3' terminal nucleotide of the ODN.

Claim 3

The oligonucleotide and crosslinking agent conjugate of claim 1 wherein the sugar moieties comprise β 2-deoxyribofuranose.

Claim 4

The oligonucleotide and crosslinking agent conjugate of claim 1 wherein the sugar moieties comprise β 2-O-methylribofuranose.

Claim 5

The oligonucleotide and crosslinking agent conjugate of claim 1 wherein q is 1.

Claim 6

The oligonucleotide and crosslinking agent conjugate of claim 1 wherein the R-LINKER-moiety is attached to the 3' end of the ODN.

Claim 7

The oligonucleotide and crosslinking agent conjugate of claim 1 wherein the R-LINKER-moiety is attached to the 5' end of the ODN.

Claim 8

The oligonucleotide and crosslinking agent conjugate of claim 1 wherein the ODN includes the sequences selected from the group consisting of 3'-TATAT and 3'-TTTTT.

Claim 9

The oligonucleotide and crosslinking agent conjugate of claim 1 wherein the R group is in accordance with formula (i).

Claim 10

The oligonucleotide and crosslinking agent conjugate of claim 1 wherein the R group is in accordance with formula (ii).

Claim 11

The oligonucleotide and crosslinking agent conjugate of claim 8 wherein the R 1 and R 2 groups jointly form a methylated pyrrol ring.

Claim 12

A covalently linked oligonucleotide and crosslinking agent conjugate wherein the sequence of the oligonucleotide is complementary or substantially complementary to a target sequence in nucleic acid, the conjugate having the formula R-LINKER-X--(P═O)(Y)--ODN where the X--(P═O)(Y)-- group is at the 3' or 5' end or at both ends of the ODN; X is O or S; Y is O - , S - or CH 3 ; ODN is an oligonucleotide of approximately 3 to 500 nucleotide units, wherein the sugar moiety attached to the heterocyclic bases of the nucleotides is independently selected from β 2-deoxyribofuranose, and β-2-OR'-ribofuranose where R' is C 1-5 -alkyl or C 2-5 -alkenyl, the internucleotide linkages may optionally and independently include phosphorothioate and methylphosphonate linkages, and the ODN may optionally include an intercalator group, reporter group, lipophilic group or a minor groove binder covalently attached to the ODN; the LINKER is a divalent moiety forming a covalent linkage between the R and (X--(P═O)( Y)) q groups, of approximately 2 to 30 atoms length, and R is a group selected from the formulas (i) and (ii) ##STR9## where R 3 is H, alkanoyl having 1 to 6 carbons, phosphoryl or trimethylsilyl; R 4 is a leaving group selected from the group consisting of Cl, Br, I and OSO 2 R" where R" is (C 1-6 )alkyl, phenyl, tolyl, bromophenyl, nitrophenyl or trifluoromethyl, and R 5 is H or alkyl of 1 to 6 carbons.

Claim 13

A covalently linked oligonucleotide and crosslinking agent conjugate wherein the sequence of the oligonucleotide is complementary or substantially complementary to a target sequence in nucleic acid, the conjugate having the formula R-LINKER-X--(P═O)(Y)--ODN where the X--(P═O)(Y)-- group is at the 3' or 5' end or at both ends of the ODN; X is O or S; Y is O - , S - or CH 3 ; ODN is an oligonucleotide of approximately 3 to 500 nucleotide units, wherein the sugar moiety attached to the heterocyclic bases of the nucleotides is independently selected from β 2-deoxyribofuranose, and β-2-OR'-ribofuranose where R' is C 1-5 -alkyl or C 2-5 -alkenyl, the internucleotide linkages may optionally and independently include phosphorothioate and methylphosphonate linkages, and the ODN may optionally include an intercalator group, reporter group, lipophilic group or a minor groove binder covalently attached to the ODN; the LINKER is a divalent moiety forming a covalent linkage between the R and (X--(P═O)( Y)) q groups, of approximately 2 to 30 atoms length, and R is a group selected from the formulas (i) and (ii) ##STR9## where R 3 is H, alkanoyl having 1 to 6 carbons, phosphoryl or trimethylsilyl; R 4 is a leaving group selected from the group consisting of Cl, Br, I and OSO 2 R" where R" is (C 1-6 )alkyl, phenyl, tolyl, bromophenyl, nitrophenyl or trifluoromethyl, and R 5 is H or alkyl of 1 to 6 carbons.

Claim 14

The oligonucleotide and crosslinking agent conjugate of claim 11 wherein the sugar moieties comprise β 2-deoxyribofuranose.

Claim 15

The oligonucleotide and crosslinking agent conjugate of claim 12 wherein R 5 is H or CH 3 .

Claim 16

The oligonucleotide and crosslinking agent conjugate of claim 13 wherein the R group is in accordance with formula (i).

Claim 17

The oligonucleotide and crosslinking agent conjugate of claim 14 wherein the R-LINKER-moiety is attached to the 3' end of the ODN.

Claim 18

The oligonucleotide and crosslinking agent conjugate of claim 14 wherein the R-LINKER-moiety is attached to the 5' end of the ODN.

Claim 19

The oligonucleotide and crosslinking agent conjugate of claim 15 wherein the LINKER is selected from the groups consisting of: --O(CH 2 ) m CO--, --O(CH 2 ) m NHCO--, --O(CH 2 ) m NHCO(CH 2 ) n CO--, --(CH 2 ) m CO--, --(CH 2 ) m CONH(CH 2 ) n CO--, --(CH 2 ) m CH(OH)(CH 2 ) n NHCO(CH 2 ) p NHCO--, ##STR10## where m, n and p are integers having such a sum total that the R group is separated by no more than approximately 30 atoms from the ODN moiety.

Claim 20

The oligonucleotide and crosslinking agent conjugate of claim 17 wherein the LINER is selected from the groups consisting of: --CO--(CH 2 ) n' --CONH--(CH 2 ) k , --CO--(CH 2 ) 2 --CONH--(CH 2 ) 2 O(CH 2 ) 2 --, --CO--(CH 2 ) n" --NHCOCH 2 -- --CO--CH 2 --, ##STR11## where n' is 2 or 3, k is 4 to 6 and n" is 2 to 5.

Claim 21

The oligonucleotide and crosslinking agent conjugate of claim 17 wherein the ODN includes the sequences selected from the group consisting of 3'-TATAT and 3'-TTTTT.

Claim 22

The oligonucleotide and crosslinking agent conjugate of claim 17 wherein X is S and the LINKER is --CO(CH 2 ) 5 NHCOCH 2 --.

Claim 23

A covalently linked oligonucleotide and crosslinking agent conjugate wherein the sequence of the oligonucleotide is complementary or substantially complementary to a target sequence in nucleic acid, the conjugate having the formula R-LINKER[X--(P═O)(Y)].sub.q --ODN where q is an integer selected from 0 or 1; the X--(P═O)(Y)-- group is at the 3' or 5' end or at both ends of the ODN; X is O or S; Y is O - , S - or CH 3 ; ODN is an oligonucleotide of approximately 3 to 500 nucleotide units, wherein the sugar moiety attached to the heterocyclic bases of the nucleotides is independently selected from β 2-deoxyribofuranose, and β-2-OR'-ribofuranose where R' is C 1-5 -alkyl or C 2-5 -alkenyl, the internucleotide linkages may optionally and independently include phosphorothioate and methylphosphonate linkages, and the ODN may optionally include an intercalator group, reporter group, lipophilic group or a minor groove binder covalently attached to the ODN; the LINKER is a divalent moiety forming a covalent linkage between the ODN and (X--(P═O)(Y)) q groups, of approximately 2 to 30 atoms length, and R is a group selected from the formulas (i) and (ii) ##STR12## where R 1 and R 2 independently are H, alkyl of 1 to 6 carbons, alkoxy of 1 to 6 carbons, phenyl, (C 1-6 alkyl)phenyl, heterocyclic consisting of a 5 membered ring and including one N as the heteroatom, (C 1-6 alkyl)heterocyclic where heterocyclic is defined as above, or the R 1 and R 2 groups jointly form a carbocyclic ring of 5 to 7 atoms, or a (C 1-6 alkyl)carbocyclic ring of 5 to 7 atoms, a heterocyclic or a (C 1-6 alkyl)heterocyclic ring where heterocyclic is defined as above, with the proviso that R 1 and R 2 are not both selected from the group consisting of phenyl, (C 1-6 alkyl)phenyl, heterocyclic and (C 1-6 alkyl)heterocyclic; R 3 is H, an alkanoyl group of 1 to 6 carbons, phosphoryl, or trialkylsilyl; R 4 is Cl, Br, I, OSO 2 R" where R" is (C 1-6 )alkyl, phenyl, tolyl, bromophenyl, nitrophenyl or trifluoromethyl, with the further proviso that when q is 0 then the LINKER group is attached to the 5 position of a uracil or to the 8 position of a purine base of a 5' or 3' terminal nucleotide of the ODN.

Claim 24

A covalently linked oligonucleotide and crosslinking agent conjugate wherein the sequence of the oligonucleotide is complementary or substantially complementary to a target sequence in nucleic acid, the conjugate having the formula R-LINKER[X--(P═O)(Y)].sub.q --ODN where q is an integer selected from 0 or 1; the X--(P═O)(Y)-- group is at the 3' or 5' end or at both ends of the ODN; X is O or S; Y is O - , S - or CH 3 ; ODN is an oligonucleotide of approximately 3 to 500 nucleotide units, wherein the sugar moiety attached to the heterocyclic bases of the nucleotides is independently selected from β 2-deoxyribofuranose, and β-2-OR'-ribofuranose where R' is C 1-5 -alkyl or C 2-5 -alkenyl, the internucleotide linkages may optionally and independently include phosphorothioate and methylphosphonate linkages, and the ODN may optionally include an intercalator group, reporter group, lipophilic group or a minor groove binder covalently attached to the ODN; the LINKER is a divalent moiety forming a covalent linkage between the ODN and (X--(P═O)(Y)) q groups, of approximately 2 to 30 atoms length, and R is a group selected from the formulas (i) and (ii) ##STR12## where R 1 and R 2 independently are H, alkyl of 1 to 6 carbons, alkoxy of 1 to 6 carbons, phenyl, (C 1-6 alkyl)phenyl, heterocyclic consisting of a 5 membered ring and including one N as the heteroatom, (C 1-6 alkyl)heterocyclic where heterocyclic is defined as above, or the R 1 and R 2 groups jointly form a carbocyclic ring of 5 to 7 atoms, or a (C 1-6 alkyl)carbocyclic ring of 5 to 7 atoms, a heterocyclic or a (C 1-6 alkyl)heterocyclic ring where heterocyclic is defined as above, with the proviso that R 1 and R 2 are not both selected from the group consisting of phenyl, (C 1-6 alkyl)phenyl, heterocyclic and (C 1-6 alkyl)heterocyclic; R 3 is H, an alkanoyl group of 1 to 6 carbons, phosphoryl, or trialkylsilyl; R 4 is Cl, Br, I, OSO 2 R" where R" is (C 1-6 )alkyl, phenyl, tolyl, bromophenyl, nitrophenyl or trifluoromethyl, with the further proviso that when q is 0 then the LINKER group is attached to the 5 position of a uracil or to the 8 position of a purine base of a 5' or 3' terminal nucleotide of the ODN.

Claim 25

The oligonudeotide and crosslinking agent conjugate of claim 21 where the R 1 and R 2 groups jointly form the heterocyclic or (C 1-6 alkyl)heterocyclic ring.

Claim 26

The oligonudeotide and crosslinking agent conjugate of claim 21 where R 3 is H.

Claim 27

The oligonucleotide and crosslinking agent conjugate of claim 21 where R 4 is Cl.

Claim 28

The oligonucleotide and crosslinking agent conjugate of claim 21 where the R 1 and R 2 groups jointly form the heterocyclic or (C 1-6 alkyl)heterocyclic ring, R 3 is H and R 4 is Cl.